摘要
目的观察阿德福韦酯联合短期恩替卡韦治疗活动性乙肝肝硬化的疗效及安全性。方法 118例活动性乙肝肝硬化患者随机分为联用组和单用组,联用组56例给予阿德福韦酯同时加用8周恩替卡韦治疗,单用组62例单用阿德福韦酯。定期检测血清HBV-DNA定量及肝肾功能等指标。结果两组患者ALT复常率、血清HBV-DNA阴转率均随着治疗疗程的延长而增加,联用组患者在治疗8周、12周及24周后,ALT复常率和HBV-DNA阴转率均比单用组疗效显著(P<0.05);联用组患者并发症发生率显著低于单用组(P<0.05)。结论阿德福韦酯联合短期恩替卡韦治疗活动性乙型肝炎肝硬化的疗效优于单用阿德福韦酯组,能更快地改善肝功能。
Objective To evaluate the efficacy and safety of adefovir dipivoxil（ADV） combined with short-term entecavir（ETV） treatment in patients with active hepatitis B cirrhosis. Methods All 118 patients with active hepatitis B cirrhosis were randomly divided into two groups： ADV group（62 patients） and ADV combined with short-term ETV group（56 patients）.The course of combined treatment lasted 8 weeks.ALT,HBV-DNA,renal function and drug adverse reactions in both groups were observed and analyzed. Results The ALT normalization rate and HBV-DNA clearance rate in ADV combined with short-term ETV group were significantly higher than those in ADV group at 8,12 and 24 weeks（P0.05）.The incidence of severe complications in ADV combined with short-term ETV was significantly lower than that in ADV group（P0.05）. Conclusion The efficacy of ADV combined with short-term ETV is superior to single ADV treatment.
出处
《胃肠病学和肝病学杂志》
CAS
2010年第9期808-810,共3页
Chinese Journal of Gastroenterology and Hepatology
